Marksans Pharma Gets USFDA Approval Benzonatate Capsules

Marksans Pharma received final USFDA approval for its ANDA for Benzonatate Capsules USP, 100 mg & 200 mg (Rx).
The product is bioequivalent to Pfizer's Tessalon Capsules and treats persistent cough, bronchitis, and lung infections.
The approval expands Marksans Pharma's upper respiratory portfolio across its globally approved manufacturing facilities.